Browsing category:

Anti-Diabetic


Recently, the Trelagliptin Succinate NDA has captured pharmaceutical headlines as it was accepted by the Japanese Ministry of Health, Labour and Welfare. As a unique once weekly treatment for type 2 diabetes, Trelagliptin Succinate is an effectual dipeptidyl peptidase-IV inhibitor. As one of the few providers in the world of Trelagliptin Succinate, LGM Pharma offers[…]

Read More

On January 24, 2014 the European Commission announced their marketing authorization to both AstraZeneca and Bristol-Myers Squibb for Xigduo. As a powerful medication for type 2 diabetes, Xigduo is a combination of Dapagliflozin and Metformin Hydrochloride, and available in two dosages: 5mg/850mg and 5mg/1,000mg tablets, respectively. This dynamic duo of powerhouse anti-diabetic medications is designed[…]

Read More

On January 24, 2014 the U.S. Food & Drug Administration {FDA} announced their approval for an abbreviated new drug application for anti-diabetic Repaglinide tablets. The generic formulation of the Prandin tablets, in both one and two milligram strengths will be produced by Perrigo. The advent of the abbreviated new drug application for Repaglinide is sure[…]

Read More

As an anti-diabetic medication and selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2), Dapagliflozin is now approved by the FDA for the treatment of type 2 diabetes mellitus. The Dapagliflozin FDA approval was announced January 13, 2014, as the brand name Farxiga, which is marketed by Bristol-Myers Squibb. The unique ability of Dapagliflozin[…]

Read More

Ranolazine shined at the American College of Cardiology’s 62nd Annual Scientific Session in Mid-March 2013 when data from a phase 4 study, coined TERISA revealed positive findings. Known as the brand name Ranexa, Ranolazine is an efficacious treatment for chronic angina. The TERISA study, standing for Type 2 Diabetes Evaluation of Ranolazine In Subjects With[…]

Read More

Liraglutide CAS No: 204656-20-2 On June 17, 2013 Endocrine Today reported at the ENDO 2013 meeting that Liraglutide demonstrated success as a weight loss treatment. Combined with the antidiabetic drug Metformin, Liraglutide was administered on a short term basis to women with polycystic ovary syndrome who were considered obese. “Obesity is a great problem in[…]

Read More

The recent announcement from actor Tom Hanks revealing his diagnosis of Type 2 diabetes was stunning for Hollywood and his numerous fans. How could Tom, an in shape and active actor have this dreadful diagnosis? Endocrinologists believe a variety of factors contributed to Tom Hanks diabetes – particularly his type 2 status, including likely genetic components, weight[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service